Mar 26, 2025
In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.
Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study.
Learning Objectives: After completing this educational activity, you should be better able to:
Activity Overview: This activity is
available with synchronized audio and is best supported via a
computer or device with current versions of the following browsers:
Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required
for print publications. A post-test score of 70% or higher is
required to receive CME/CE credit.
Estimated Time to Complete: 1 hour.
Released: March 26, 2025*
Expiration: March 25, 2028
*NEI maintains a record of participation for six (6)
years.
CME/CE Credits and Certificate Instructions:
After listening to the podcast, to take the optional posttest and
receive CME/CE credit, click:
https://nei.global/POD25-01
Credit Designations: The following are being
offered for this activity:
Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented.
Faculty Author / Presenter
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and
Behavioral Sciences, Norton College of Medicine, State University
of New York Upstate Medical University, Syracuse, New York
Chief Medical Officer, Neuroscience Education Institute,
Malvern, Pennsylvania
Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome,
Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel,
Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular,
Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye,
MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven,
Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion),
Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics
Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome,
BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen,
Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion),
Supernus, Takeda, Teva, Tris Pharma, Vanda
Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom
Biosciences
Faculty Author / Presenter
Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and of Pharmacology,
University of Toronto, Toronto, Ontario, Canada
CEO, Braxia Scientific Corp, Toronto, ON, Canada
Grant/Research: Canadian Institutes of Health Research, China
National Natural Research Foundation, Global Alliance for Chronic
Diseases, Milken Institute
Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch
Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck,
Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge
Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage,
Sanofi, Sunovion, Takeda, Viatris
The remaining Planning Committee members, Content Editors, Peer
Reviewer, NEI and HMP planners/staff have no financial
relationships to disclose. NEI and HMP Education planners and staff
include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD,
CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me.
For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com.
Support: This activity is supported solely by the provider, NEI.